Drugs / MMV371
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07548021 | Sep 2026 → Mar 2028 expected | Plasmodium falciparum malaria, parasitemia | Medicines for Malaria Venture | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07011511 | Jun 2025 → Dec 2027 expected | Plasmodium falciparum malaria | Medicines for Malaria Venture | Recruiting | No outcome recorded |
| Phase 1 | NCT06558643 | Aug 2024 → Sep 2025 | Plasmodium falciparum malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMV371 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07011511 ↗ |
| Route | Intramuscular | “Single intra-muscular dose” NCT06558643 ↗ |